


Product Details

Product name:	Anti-human TSLP (tezepelumab Biosimilar)	SKU:	BIO0847SM
Target Name:	TSLP	Size:	1 mg/5 mg/20 mg
Target Uniprot:	Q969D9	Concentration:	Lyophilized
Clone#:	tezepelumab	Isotype:	Human IgG2
Reactivity:	Human, Cynomolgus	Calculated M.W.:	144.6 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	0.1M Pro, 20mM Arg, pH5.0	Conjugation:	None
Storage:	For long term storage, the produce should be stored at -20° C or lower.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH2O	Purification:	Protein A


Data

Purity:SDS-PAGE




Anti-TSLP (tezepelumab) on SDS-PAGE underreducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC




The purity of Anti-TSLP (tezepelumab) is 98.64%, determined by SEC-HPLC.

Bioactivity:ELISA



Immobilized human TSLP His at 2 ug/mL can bind Anti-TSLP (tezepelumab), EC50=0.0518 ug/mL.


Function:Blocking



Anti-TSLP (tezepelumab)-induced FACS Blocking activity was evaluated using TSLPR/IL7R-CHO-K. The IC50 was approximately 0.0802 ug/mL.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Research in vivo



Tezepelumab reduced levels of IL13 in BALF of OVA asthma model on B-hTSLP/hTSLPR mice. The result showed significant IL13 inhibition effects at 15 mpk.